AAV2/8 LSPhGAA 在晚发性庞贝病中的安全性 I 期研究-猫眼课题宝

AAV2/8 LSPhGAA 在晚发性庞贝病中的安全性 I 期研究

批准号：

9309362

负责人：

Dwight D Koeberl

金额：

$37.1万

依托单位：

DUKE UNIVERSITY

依托单位国家：

美国

项目类别：

财政年份：

2017

资助国家：

美国

项目状态：

已结题

起止时间：

2017-09-05 至 2020-06-30

来源：

https://reporter.nih.gov/project-details/9309362

关键词：

Acids Address Adult Advisory Committees Antibodies Antibody Formation Antibody Response Biological Markers Clinical Clinical Investigator Clinical Protocols Clinical Research Clinical Trials Data Development Dose Glucan 1,4-alpha-Glucosidase Glycogen Glycogen storage disease type II Goals Health Benefit Hemophilia B Human Immune response Immunoblotting Infusion procedures Institutes Investigational Drugs Investigational New Drug Application Liver Measurement Mediating Medical Monitor Muscle Myocardium Myopathy Outcome Patients Phase I Clinical Trials Plasma Production Public Health Publications Pulmonary function tests Rare Diseases Recombinant DNA Recombinants Research Institute Research Personnel Safety Scientist Skeletal Muscle Smooth Muscle Specialist Striated Muscles Testing Toxic effect United States Food and Drug Administration Walking adeno-associated viral vector base clinical translation clinically significant curative treatments design dosage enzyme replacement therapy gene therapy gene therapy clinical trial glucosidase human subject improved infancy mortality novel therapeutics phase 1 study pre-clinical preclinical development receptor safety study uptake urinary vector

项目摘要

项目成果

Dwight D Koeberl的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Project Summary The development of gene therapy has advanced to a point where a cure for Pompe disease can be foreseen. Pompe disease (glycogen storage disease type II; acid maltase deficiency) is a devastating myopathy resulting from acid alpha-glucosidase (GAA) deficiency in striated and smooth muscle. Despite the availability of enzyme replacement therapy (ERT) with recombinant human (rh) GAA, many patients have poor outcomes including mortality due to clinically significant anti-GAA antibody response. The limitations of ERT have prompted the preclinical development of gene therapy for Pompe disease. Clinical translation of efficacious gene therapy will greatly advance treatment for Pompe disease by correcting GAA deficiency and suppressing immune responses against rhGAA.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文